Table 2.
Correlation between expression levels of serum exosomal aHIF and clinicopathological characteristics
| Variable | Low expression of exosomal aHIF (n=31) | High expression of exosomal aHIF (n=31) | P |
|---|---|---|---|
| Age (years) | |||
| <50 | 11 (35.5%) | 13 (41.9%) | 0.153 |
| ≥50 | 20 (64.5%) | 18 (58.1%) | |
| Stage | <0.01 | ||
| I–II | 19 (61.3%) | 3 (9.7%) | |
| III–IV | 12 (38.7%) | 28 (90.3%) | |
| Histological type | 0.106 | ||
| Serous | 22 (71.0%) | 27 (87.1%) | |
| Others | 9 (29.0%) | 4 (12.9%) | |
| Histological grade | <0.01 | ||
| G1–G2 | 19 (61.3%) | 7 (22.6%) | |
| G3 | 12 (38.7%) | 24 (77.4%) | |
| Residual tumor diameter (cm) | 0.127 | ||
| ≤1 | 25 (80.6%) | 20 (64.5%) | |
| >1 | 6 (19.4%) | 11 (35.5%) | |
| Ascites (mL) | 0.500 | ||
| <100 | 10 (32.2%) | 9 (29.0%) | |
| ≥100 | 21 (67.7%) | 22 (71.0%) | |
| CA125 (U/mL) | 0.153 | ||
| <600 | 15 (48.4%) | 20 (64.5%) | |
| ≥600 | 16 (51.6%) | 11 (35.5%) |
Abbreviations: EOC, epithelial ovarian cancer; aHIF, antisense hypoxia inducible factor.